Skip to main content

Table 2 Cox proportional hazard analyses of adverse long-term event outcomes

From: The role of Asprosin in patients with dilated cardiomyopathy

Variable Univariate analysis
HR (95% CI) P value
Asprosin (< 120 vs ≥120 ng/mL) 7.94 (1.88–33.50) 0.005
Age, y 0.93 (0.87–1.00) 0.04
Female gender, n (%) 0.83 (0.14–4.8) 0.83
Body mass index, kg/m2 0.09 (−0.06–0.23) 0.24
Hypertension, n (%) 1.26 (0.34–4.65) 0.73
Diabetes mellitus, n (%) 0.08 (−1.30–1.46) 0.91
NYHA class III or IV, n (%) 0.70 (0.18–2.67) 0.60
Atrial fibrillation, n (%) 1.26 (0.36–4.34) 0.72
LV mass index, g/m2 1.00 (0.99–1.01) 0.793
LV end-diastolic volume index, mL/m2 1.00 (0.99–1.01) 0.28
LV ejection fraction, % 0.92 (0.84–0.99) 0.03
Mitral E/A ratio 1.33 (0.46–3.86) 0.60
BNP, pg/mL 1.00 (0.99–1.00) 0.20
eGFR, mL/min/1.73 m2 1.00 (0.98–1.03) 0.79
Creatinine, mg/dL 0.66 (0.25–1.76) 0.40
Cholesterol, mg/dL 0.97 (0.95–0.99) 0.007
Sugar, mg/dL 0.98 (0.95–1.02) 0.32
  1. BNP B-type natriuretic peptide, eGFR estimated glomerulus filtration rate, LVEF left ventricle ejection fraction, NYHA New York Heart Association